Cybin Inc
CYBN
查看详细走势图
7.175USD
-0.005-0.07%
收盘 12/22, 16:00（美东）报价延迟15分钟
187.28M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.07%
5天
+7.41%
1月
+28.35%
6月
-7.78%
今年开始到现在
-18.65%
1年
-25.34%
查看详细走势图
TradingKey Cybin Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
Cybin Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名32/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价58.17。中期看，股价处于上升通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Cybin Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
7
位分析师
买入
评级
58.167
目标均价
+884.21%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Cybin Inc亮点
亮点风险
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. It has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值高估
公司最新PE估值-1.83，处于3年历史高位
机构加仓
最新机构持股13.64M股，环比增加21.96%
Cybin Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Cybin Inc简介
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. It has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
公司代码CYBN
公司Cybin Inc
CEOSo (Eric How-Lun)
网址https://www.cybin.com
常见问题
Cybin Inc(CYBN)的当前股价是多少？
Cybin Inc(CYBN)的当前股价是 7.175。
Cybin Inc的股票代码是什么？
Cybin Inc的股票代码是CYBN。
Cybin Inc股票的52周最高点是多少？
Cybin Inc股票的52周最高点是15.550。
Cybin Inc股票的52周最低点是多少？
Cybin Inc股票的52周最低点是6.950。
Cybin Inc的市值是多少？
Cybin Inc的市值是187.28M。
Cybin Inc的净利润是多少？
Cybin Inc的净利润为-113.14M。
现在Cybin Inc(CYBN)的股票是买入、持有还是卖出？
根据分析师评级，Cybin Inc(CYBN)的总体评级为买入，目标价格为58.167。
Cybin Inc(CYBN)股票的每股收益（EPS TTM）是多少
Cybin Inc(CYBN)股票的每股收益（EPS TTM）是-3.922。
相关品种
